InvestorsHub Logo
Followers 2
Posts 2974
Boards Moderated 0
Alias Born 06/23/2017

Re: FDApproved post# 8753

Thursday, 11/30/2017 9:10:02 PM

Thursday, November 30, 2017 9:10:02 PM

Post# of 44784
Ok you don't have to ask. Here's the third. Care to explain how they are directly getting 100% of the funds? I won't hold my breath. Maybe Lonza will purchase the Centers running these things, and when the big Lonza deal comes any day now, it will just be like getting it all. Or Amgen could be a possibility I guess. LMBO

In September 2017, our Phase III study of PLX-PAD cells to support recovery following surgery for femoral neck fracture was awarded a Euro 7,400,000 (approximately $8,700,000) grant. The grant is part of the European Union's Horizon 2020 program. The Phase III study of PLX-PAD to support recovery following surgery for femoral neck fractures will be a collaborative project carried out by an international consortium led by Charite Universitätsmedizin Berlin, together with us, and with participation of additional third parties. The grant will cover a significant portion of the project costs. An amount of Euro 2,400,000 (approximately $2,800,000) is a direct grant allocated to us for manufacturing and other costs, and we also expect to have a direct benefit from cost savings resulting from grant amounts allocated to the other consortium members.